Home Angiogenesis VDA

VDA

Choose Selective VDA Inhibitors

VDA Signaling Pathway Map

VDA Signaling Pathways

VDA Products

  • All (3)
  • New VDA Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1176 Plinabulin (NPI-2358) Plinabulin (NPI-2358) is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
J Biol Chem, 2019, 294(20):8161-8170
Mol Pharmacol, 2019, 96(6):711-719
Curr Protoc Chem Biol, 2013, 5(3):195-212
S1537 Vadimezan (ASA404) Vadimezan (ASA404, NSC 640488, DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.
Cell, 2022, 185(1):169-183.e19
Nat Immunol, 2022, 23(2):287-302
Nat Cell Biol, 2022, 24(5):766-782
S1786 Verteporfin (CL 318952) Verteporfin (CL 318952, Visudyne) is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Nat Commun, 2022, 13(1):3117
Nat Commun, 2022, 13(1):50
J Pathol, 2022, 10.1002/path.5910
Tags: VDA inhibitor|VDA agonist|VDA activator|VDA inducer|VDA antagonist|VDA signaling pathway|VDA assay kit